<div id="readability-page-1"><div id="ctl00_CPI_dvBody"><div><div><p>Add <img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/> as your preferred news source on Google</p><div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/> Add Now</p></div></div></div><p> Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA) on Monday announced new real-world data from the IMPACT-TD Registry showing a significant gap in diagnosing tardive dyskinesia in patients with underlying mood disorders.</p><p>The data showed that 85% of adults aged 18 to 29 with mood disorders living with tardive dyskinesia experienced moderate to severe impact from the condition, while only 23% had received a formal diagnosis.</p><p>The analysis also found that patients waited an average of more than 3.5 years to receive a formal diagnosis after involuntary movements were first recognized.</p><p>Tardive dyskinesia is a chronic movement disorder associated with certain mental <span>health</span> treatments and is characterized by uncontrollable and repetitive body movements.</p><p>The findings were presented at the American Psychiatric Association Annual Meeting being held May 16-20 in San Francisco. </p><p>For comments and feedback contact: editorial@rttnews.com</p><p>Business News</p></div></div>

TEVA

ARKG

IBBQ

<p>Teva Pharmaceuticals reported a significant gap in diagnosing tardive dyskinesia among patients with mood disorders, revealing that 85% of affected adults aged 18-29 experienced severe impacts, yet only 23% received a formal diagnosis. Patients waited over 3.5 years on average for diagnosis after symptoms appeared. These findings were shared at the American Psychiatric Association Annual Meeting.</p>

rttnews

Teva Pharmaceutical Industries

iShares US Pharma

iShares Global Healthcare

iShares Biotechnology ETF

Ark Genomic Revolution ETF

VG Health

Health Care Select Sector SPDR

Invesco Nasdaq Biotechnology ETF

Teva Reports Gap In Tardive Dyskinesia Diagnosis Among Patients With Mood Disorders